RNA polymerase II associated protein 1Genealiases: []
Q-omics provides the consensus-scored RPAP1 profile across patient tissues and cancer cell-line models. RPAP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPAP1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RPAP1 RNA expression shows 20,130 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, COAD, and ACC as cancer lineages where RPAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPAP1 survival associations across molecular data types. RPAP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPAP1 RNA expression–survival associations across cancer types. High RPAP1 expression shows unfavorable associations in BLCA, CESC, KIRP and LUAD, but favorable associations in KIRC and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for RPAP1 RNA expression.
This table summarizes RPAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPAP1 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, HNSC, STAD and KIRP. The COAD box plot shows higher RPAP1 RNA expression in tumor versus normal tissue (log2 FC = +0.648, t-test p < 0.001).
This table shows molecular features associated with RPAP1 in patient tissues and cancer cell lines. In patient samples, RPAP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
